The Pharmaletter
One To Watch
Cocrystal Pharma
A US biotech company discovering and developing antiviral compounds to treat viral infections including coronavirus and influenza virus infections by leveraging its proprietary drug discovery platform.
Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create its antiviral drugs.
In December 2020, the company announced the selection of CDI-45205 as its lead coronavirus development candidate among a group of protease inhibitors obtained under an exclusive license agreement with Kansas State University Research Foundation.
Latest Cocrystal Pharma News
28 November 2014
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze